Antitope seals research agreement with Boehringer

Antitope Ltd of Cambridge, agreed a research deal with Boehringer Ingelheim for the modification of monoclonal antibodies. The collaboration will see Antitope apply its proprietary Composite Human Antibody technology to humanise certain of Boehringer’s therapeutic antibodies, thus reducing their immunogenicity.

Matthew Baker, Chief Scientific Officer and co-founder of Antitope said, “This partnership utilises Antitope's expertise in creating humanised antibodies devoid of T cell epitopes to complement Boehringer Ingelheim’s innovation in developing novel therapeutics based on monoclonal antibodies.”